SCYNEXIS (STU:135A) 3-Year Share Buyback Ratio : -9.80% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SCYNEXIS 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. SCYNEXIS's current 3-Year Share Buyback Ratio was -9.80%.

The historical rank and industry rank for SCYNEXIS's 3-Year Share Buyback Ratio or its related term are showing as below:

STU:135A' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -106.5 Med: -50.75 Max: -9.8
Current: -9.8

During the past 13 years, SCYNEXIS's highest 3-Year Share Buyback Ratio was -9.80%. The lowest was -106.50%. And the median was -50.75%.

STU:135A's 3-Year Share Buyback Ratio is ranked worse than
70.28% of 673 companies
in the Drug Manufacturers industry
Industry Median: -2.4 vs STU:135A: -9.80

Competitive Comparison of SCYNEXIS's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

SCYNEXIS 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

SCYNEXIS (STU:135A) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

SCYNEXIS 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (STU:135A) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

SCYX:USA 0L49:UK

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

SCYNEXIS Headlines

No Headlines